

Davidson, Mark

From: Davidson, Mark
Sent: Wednesday, August 23, 2017 11:05 AM
To: 'Rizwana Sproule'
Cc: 'Alex Babayan'; 'Nadia Agopyan'
Subject: Kite Pharma 125643 Clinical IR 8.23.17

Importance: High

Dear Dr. Sproule,

The current ZUMA 1 protocol, section 6.2 (study treatment schedule) refers the reader to the investigational product manual for details on KTE-C19 storage and administration. Clarify the location of this manual, or submit this manual for review.

Please respond by August 24, 2017.

Thank You

Mark L. Davidson, RHIA
Regulatory Project Manager
OTAT/CBER/FDA
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 240-402-8277
Fax:301-595-1303
mark.davidson@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."